I think the goal of informing consumers that the A1-laden milk they are consuming is causing small bowel inflammation as compared to pure A2 milk, worthwhile. This would then encourage them to try the milk to assess whether their long term dairy intolerance is related to the A1 protein rather than just assuming it is lactose intolerance.
A2M regularly comment that the incidence of self reported lactose intolerance is way above the epidemiological percentages. Their entire long term business case is based heavily on this difference, IMO. Long term investors should do the research and make sure they understand this position. It's what makes A2 an incredible opportunity if they can provide more and more scientific evidence to back up. There are more papers out there for those who want to research as well as some awaiting publication.
A2M Price at posting:
$1.05 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)